HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape
International Journal of Molecular Sciences · 02.03.2026 · 27 (5) · 2334
DOI: 10.3390/ijms27052334 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.03.2026. Verfasst von Paola Muscolino und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the past decade, significant achievements in elucidating the molecular pathogenesis of non–small cell lung cancer (NSCLC) have catalyzed a paradigm shift from empiric therapies to precision oncology. In this context, HER2 alterations, including protein overexpression, gene amplification, and activating mutations, constitute distinct molecular subsets within NSCLC. In the past few years, targeted therapeutic modalities such as antibody–drug conjugates (ADCs), particularly trastuzumab deruxtecan (the first agent to be granted FDA approval for HER2-mutant NSCLC), alongside selective tyrosine kinase inhibitors (TKIs), including zongertinib and sevabertinib, have demonstrated robust systemic efficacy and notable intracranial penetration. This comprehensive review delineates the molecular landscape and clinical phenotypes of HER2-altered NSCLC, synthesizes interim and mature data from ongoing clinical trials evaluating anti-HER2 therapies, and critically examines efficacy and safety results from different classes of targeted agents. Further research is crucial to uncover potential mechanisms of resistance in NSCLC with HER2 mutations and define sequencing or combinatorial strategies pertinent to optimizing individualized patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.
- Department of Medical Oncology, Candiolo Cancer Institute-FPO-IRCCS, 10060 Candiolo, Italy.
- Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy.
- Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
- Medicine and Surgery Department, University of Milano Bicocca, 20900 Milan, Italy.
ORCID-Profile: Francesca Colonese, Giuliana Ciappina, Massimiliano Berretta, Vanesa Gregorc
Zitieren
APA
Muscolino, P., Fassi, E., Signorelli, D., Colonese, F., Cortinovis, D. L., Lo Russo, G., Pasello, G., Infurna, C., Ciappina, G., Berretta, M., Gregorc, V., Lazzari, C., & Santarpia, M. (2026). HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape. International Journal of Molecular Sciences, 27(5), 2334. https://doi.org/10.3390/ijms27052334
Vancouver
Muscolino P, Fassi E, Signorelli D, Colonese F, Cortinovis DL, Lo Russo G, et al. HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape. International Journal of Molecular Sciences. 2026;27(5):2334. doi:10.3390/ijms27052334
BibTeX
@article{Muscolino2026,
author = {Muscolino, Paola and Fassi, Elena and Signorelli, Diego and Colonese, Francesca and Cortinovis, Diego Luigi and Lo Russo, Giuseppe and Pasello, Giulia and Infurna, Carla and Ciappina, Giuliana and Berretta, Massimiliano and Gregorc, Vanesa and Lazzari, Chiara and Santarpia, Mariacarmela},
title = {HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {5},
pages = {2334},
doi = {10.3390/ijms27052334}
}
EUVIMED